US Agent vs US Sponsor of Record: Which One Does a Foreign IDE Sponsor Actually Need?

The Confusion That Can Derail Your IDE Before It Starts

If your company is headquartered outside the United States and you are planning to conduct an Investigational Device Exemption (IDE) study on US soil, you have almost certainly encountered two terms that sound interchangeable but carry very different regulatory obligations: US Agent and US Sponsor of Record. Conflating these two roles is one of the most common -- and most consequential -- mistakes foreign device companies make when entering the US clinical trial landscape.

Getting this wrong does not just create administrative headaches. It can result in FDA rejections, clinical holds, or enforcement actions that stall your entire US market strategy. This post breaks down exactly what each role means, the specific regulatory authority behind each, and how to determine which one your organization actually needs.

What a US Agent Is -- and What It Is Not

The US Agent requirement for foreign device establishments is codified under 21 CFR 807.40. Under this regulation, any foreign establishment that manufactures, prepares, propagates, compounds, or processes a device that is imported or offered for import into the United States must designate a US Agent. The US Agent serves as FDA's primary point of contact for that establishment -- receiving communications, facilitating inspections, and ensuring the foreign firm is reachable during business hours.

Critically, the US Agent role is tied to device listing and establishment registration, not to the conduct of a clinical investigation. A US Agent does not assume legal responsibility for the IDE application. They do not sign IDE submissions. They are not the entity FDA holds accountable for the investigational plan, informed consent processes, or IRB oversight.

In practical terms, a US Agent is a communications conduit. It is a necessary role for many foreign firms, but it is not the role that governs clinical trial sponsorship under IDE regulations.

What a US Sponsor of Record Actually Means Under IDE Regulations

The IDE regulatory framework lives primarily in 21 CFR Part 812. Under 21 CFR 812.3(n), a sponsor is defined as a person who initiates, but who does not actually conduct, the investigation -- the entity that takes responsibility for and initiates a clinical investigation. The sponsor submits the IDE application, assumes legal accountability for the study's conduct, and is the entity with whom FDA formally communicates regarding the investigation.

FDA's guidance document 'Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human Studies' (October 2013) and the broader IDE regulations make clear that the sponsor must be an identified legal entity capable of fulfilling all obligations under 21 CFR Part 812. These obligations include:

• Submitting and maintaining the IDE application
• Ensuring proper monitoring of the clinical investigation
• Maintaining required records and making them available to FDA
• Ensuring IRB review and approval are obtained
• Reporting adverse device effects and deviations to FDA under the timelines specified in 21 CFR 812.150

When a foreign company sponsors a US IDE study, FDA expects a clearly identified sponsor of record. While the regulations do not explicitly prohibit a foreign entity from being the sponsor, the practical reality is that FDA communications, inspection requests, and enforcement actions require a reliably reachable, legally accountable US presence. Many foreign sponsors address this by designating a US-based sponsor representative or by formally transferring sponsorship obligations to a US entity through a Sponsor-Investigator arrangement or a contract research organization (CRO) acting as a co-sponsor -- provided the arrangement is explicitly documented and FDA is notified.

The Four Scenarios Foreign IDE Sponsors Actually Face

Scenario 1: Foreign Sponsor, No US Manufacturing

If your device is manufactured abroad and you have not yet registered a US establishment, you may not yet have a US Agent on file. You will need one before importing devices for the study. But your more immediate concern is designating a sponsor of record for the IDE submission itself.

Scenario 2: Foreign Sponsor With a US Subsidiary

This is the cleanest structure. Your US subsidiary can serve as the IDE sponsor of record, assume all 21 CFR Part 812 obligations, and also fulfill the US Agent function for the parent establishment if needed. FDA prefers clear lines of accountability, and a US legal entity as sponsor provides exactly that.

Scenario 3: Foreign Sponsor Using a CRO as Sponsor Representative

Under 21 CFR 812.40, a sponsor may transfer any or all of its obligations to a CRO, but the transfer must be documented in writing and submitted to FDA. The sponsor retains ultimate legal responsibility for any obligations not explicitly transferred. This arrangement requires careful contract drafting and proactive communication with FDA about the division of responsibilities.

Scenario 4: No US Presence Whatsoever

This is the highest-risk scenario. Foreign sponsors without any US entity, subsidiary, or formally designated US sponsor representative face significant logistical and regulatory challenges. FDA has, in practice, issued IDE approvals to foreign sponsors, but ongoing correspondence, inspection readiness, and adverse event reporting timelines are all more difficult to manage. Establishing a formal US presence -- even a lean one -- is almost always the right strategic move before IDE submission.

The Bottom Line: Which Do You Actually Need?

Most foreign IDE sponsors need both -- but for different reasons and at different stages. The US Agent satisfies your establishment registration obligations under 21 CFR 807.40 and is required before you can import investigational devices. The sponsor of record designation under 21 CFR Part 812 is what governs your IDE application and clinical study conduct.

Do not make the mistake of thinking that appointing a US Agent checks the box for IDE sponsorship. It does not. These are separate regulatory obligations with separate regulatory consequences.

Work With a Firm That Knows the Difference

At ADB Consulting and CRO Inc., we help foreign medical device companies structure their US clinical strategy correctly from day one -- before the first FDA submission is filed. Whether you need help designating the right sponsor structure, navigating IDE pre-submissions, or managing ongoing 21 CFR Part 812 compliance, our team brings deep, practical regulatory expertise to every engagement.

Do not let a structural oversight slow down your path to US market clearance. Book a free discovery call with Andre Butler today at adbccro.com and get clarity on exactly what your organization needs to move forward with confidence.

If this applies to your program, our US Agent service walks through the process in detail.